What you need to know
- 1.20Antihypertensives, statins, anticoagulants and plateletA cell fragment in the blood. At a damaged vessel wall, platelets stick together and release thromboplastin. inhibitors: benefits and risks.
By the end, you should be able to…
- Explain what each treatment group changes.
- Distinguish inhibition of clotting factors from inhibition of platelets.
- Evaluate benefits against harms using supplied evidence.
Build your understanding
Reduce pressure or reduce LDL
Antihypertensives lower blood pressureThe pressure that blood exerts on the walls of the blood vessels.. Different classes act in different ways, for example by reducing blood volume or relaxing blood vessels. Lower pressure can reduce stress on vessel walls and cardiovascular risk. Excessive pressure reduction can cause dizziness or faintness; other adverse effects depend on the drug class.
Statins inhibit an enzyme involved in cholesterolA lipid found in cell membranes. High levels of LDL cholesterol in the blood are a risk factor for atheroma. synthesis in the liver, reducing LDLLow-density lipoprotein. It carries cholesterol from the liver to the tissues. High LDL is linked to atheroma. cholesterol and the risk of cardiovascular events in appropriate patients. Possible adverse effects include muscle symptoms and changes in liver enzymeA globular protein that acts as a biological catalyst, speeding up a specific reaction.; serious muscle injury is rare. Benefits and risks depend on baseline risk and the individual treatment context.
Reduce harmful clot formation
Anticoagulants interfere with the clotting cascade, reducing formation of fibrinInsoluble protein threads that form a mesh, trapping blood cells to make a clot. and limiting harmful clot formation or extension. They do not make the blood literally thinner and are not the same as drugs that dissolve an existing clot. Their major risk is increased bleeding.
plateletA cell fragment in the blood. At a damaged vessel wall, platelets stick together and release thromboplastin. inhibitors reduce platelet activation or aggregation; aspirin is one example. They can reduce platelet-rich thrombusA blood clot that forms inside a blood vessel. formation in relevant cardiovascular settings. Increased bleeding, including gastrointestinal bleeding with aspirin, is an important risk. Anticoagulants and platelet inhibitors affect different parts of haemostasis and are not interchangeable labels.
Compare outcomes rather than choosing a universal winner
A treatment may reduce one outcome while increasing another. Compare the size of absolute benefits and harms, their severity, follow-up period and the populationAll the individuals of one species living in one area at the same time. studied. The same relative reduction produces a larger absolute benefit where baseline risk is higher.
These are educational mechanisms, not a prescribing guide. A classroom question may ask you to evaluate supplied trial evidence; it does not provide enough information to choose, start or stop a medicine for a person. Use the evidence given and state its limits.
NOT: anticoagulants do not dissolve an existing clot, and they are not platelet inhibitors.
- Statins act on cholesterol synthesis, not on the clot itself
- Anticoagulant: clotting cascade. Platelet inhibitor: platelets
- The same relative benefit is a larger absolute benefit at higher baseline risk
- These are mechanisms for study, not a reason to choose a medicine
Two traps this diagram blocks
- Do not use anticoagulant and platelet inhibitor as two names for the same drug.
- Do not say every drug in a group has the same side-effect frequency.
From the diagram alone
Question
Explain the difference between an anticoagulant and a platelet inhibitor, and state one shared risk. [3]
Show a model answer
An anticoagulant reduces the clotting cascade and therefore fibrin formation. A platelet inhibitor reduces platelet activation or aggregation. Both can increase the risk of bleeding. Neither name means the drug dissolves a clot that is already formed.
| Group | Main target | Example risk |
|---|---|---|
| Antihypertensives | Blood pressure | Excessive pressure reduction; class-specific effects |
| Statins | Cholesterol synthesis / LDL | Muscle symptoms; liver-enzyme changes |
| Anticoagulants | Clotting cascade / fibrin formation | Bleeding |
| Platelet inhibitors | Platelet activation / aggregation | Bleeding |
Make your reasoning visible
Keep the four targets distinct
Antihypertensives: pressure. Statins: cholesterolA lipid found in cell membranes. High levels of LDL cholesterol in the blood are a risk factor for atheroma. synthesis and LDLLow-density lipoprotein. It carries cholesterol from the liver to the tissues. High LDL is linked to atheroma.. Anticoagulants: clotting cascade. plateletA cell fragment in the blood. At a damaged vessel wall, platelets stick together and release thromboplastin. inhibitors: platelet activation or aggregation.
Balance benefit and risk
Explain the mechanism of benefit and a relevant adverse effect. Avoid saying that every drug in a group has the same side-effect frequency.
Key explanations
- Both anticoagulant and antiplatelet treatment can increase bleeding, but they act on different steps.
- A larger baseline risk means the same relative reduction prevents more events. It does not remove the need to weigh harms.
Avoid this misconception
The claim: Anticoagulants and platelet inhibitors are both clot-dissolving drugs.
The correction: They reduce different processes in clot formation. Neither label means direct dissolution of an existing clot; clot-dissolving treatments are a separate category.
Check your understanding
Try each question before opening the suggested answer.
Practice question
Retrieval and explanation · suggested answer
Explain why a medicine that reduces fibrin formation may increase bleeding risk.
Show suggested answer
Fibrin helps stabilise a haemostatic plug. Inhibiting its formation can reduce harmful thrombosis but also impair normal stopping of bleeding after injury.
Practice question
Retrieval and explanation · suggested answer
In fictional equal groups followed for five years, a treatment prevents 20 cardiovascular events per 1000 people and causes 5 additional serious bleeds per 1000. Is subtracting to give “15 benefits” sufficient evaluation?
Show suggested answer
No. Events may differ in severity and may occur in the same people. Consider the defined outcomes, uncertainty, baseline risk and consequences of each, rather than treating all events as interchangeable.
Take the idea further
Apply the same specification knowledge to an unfamiliar problem. Any extra assumptions are supplied in the question.
Stretch question
A drug gives a 25% relative reduction in a defined event. Baseline five-year risks are 12% in group A and 4% in group B. Assuming the effect applies equally, calculate treated risks and absolute reductions.
Show a hint
Multiply each baseline risk by 0.75.
Explore the reasoning
Treated risks are 9% in A and 3% in B. Absolute reductions are 3 and 1 percentage points respectively. Equal relative benefit therefore does not imply equal absolute benefit; harms must also be assessed.
Recall this lesson
Lesson recall questions
Question 1 of 5: State the intended benefit of an antihypertensive, and one named risk.
CVD treatments: benefit and risk
Practice question
Retrieval and explanation · suggested answer
State the intended benefit of an antihypertensive, and one named risk.
Lesson: 1C 7: The Benefits and Risks of Treatment
Try this from memory first.
Put your biology to work
Explore where these ideas appear in the world. Enrichment, not extra required recall.
Why “best medicine” needs a context
1C · The Benefits and Risks of TreatmentNHLBI describes several medicine groups used in coronary heart disease, acting on different parts of the disease process. This illustrates why matching a treatment to a clinical situation…Specification 1.20Read & use the scienceClose article
Why this matters
NHLBI describes several medicine groups used in coronary heart disease, acting on different parts of the disease process. This illustrates why matching a treatment to a clinical situation requires more than knowing one mechanism. A medicine reducing platelet aggregation targets a different step from one lowering blood pressure or cholesterol. The expected benefit also depends on the person’s starting risk and the outcome being prevented. For a clinical researcher, the question is not just whether a mechanism works, but how often important benefits and harms occur in an appropriate comparison group. This makes the specification’s evaluation of benefits and risks practical: a plausible action alone cannot identify the best treatment for everyone.
Back to the specification
Pearson Edexcel IAL Biology · Issue 2, February 2021 · Unit 1, pp. 15–18. The application extends beyond required recall.
- 1.20 know the benefits and risks of treatments for cardiovascular disease (CVD) (antihypertensives, statins, anticoagulants and platelet inhibitors)
Use the science
Why is “this medicine prevents clots, so everyone should take it” an unjustified claim?
Explore a possible response
Baseline clot risk varies, while medicines can cause harms such as bleeding. Evidence from one patient group may not apply to everyone, and individual decisions need clinical assessment.
Explore the source
Testing a side effect without dismissing it
1C · The Benefits and Risks of TreatmentThe SAMSON trial studied people who had stopped statins because of symptoms. Participants experienced periods with statin tablets, placebo tablets and no tablets, allowing researchers to compare symptom…Specification 1.16 · 1.20Read & use the scienceClose article
Why this matters
The SAMSON trial studied people who had stopped statins because of symptoms. Participants experienced periods with statin tablets, placebo tablets and no tablets, allowing researchers to compare symptom patterns within individuals. Symptoms during placebo and statin periods were similar on average. This illustrates the nocebo effect: expectations and the experience of treatment can contribute to symptoms. The symptoms are real; the result does not mean every adverse reaction is imagined or that statins cannot cause harm. The study shows why evaluating a treatment requires a suitable comparison and attention to the population actually recruited.
Back to the specification
Pearson Edexcel IAL Biology · Issue 2, February 2021 · Unit 1, pp. 15–18. The application extends beyond required recall.
- 1.16 be able to evaluate the design of studies used to determine health risk factors, including sample selection and sample size used to collect data that is both valid and reliable
- 1.20 know the benefits and risks of treatments for cardiovascular disease (CVD) (antihypertensives, statins, anticoagulants and platelet inhibitors)
Use the science
What does the no-tablet period help distinguish that a statin-versus-placebo comparison alone cannot?
Explore a possible response
It helps separate background symptoms from symptoms associated with taking a tablet and treatment expectations. A placebo arm alone cannot quantify the no-tablet baseline.
Explore the source
- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No TreatmentHoward et al., Journal of the American College of Cardiology (2021)